SG11201908181XA - Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof - Google Patents
Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereofInfo
- Publication number
- SG11201908181XA SG11201908181XA SG11201908181XA SG11201908181XA SG 11201908181X A SG11201908181X A SG 11201908181XA SG 11201908181X A SG11201908181X A SG 11201908181XA SG 11201908181X A SG11201908181X A SG 11201908181XA
- Authority
- SG
- Singapore
- Prior art keywords
- malvern
- pennsylvania
- international
- rule
- spring mill
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title abstract 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467752P | 2017-03-06 | 2017-03-06 | |
| US201762467750P | 2017-03-06 | 2017-03-06 | |
| US201762564989P | 2017-09-28 | 2017-09-28 | |
| US201762564990P | 2017-09-28 | 2017-09-28 | |
| PCT/US2018/020968 WO2018165048A1 (fr) | 2017-03-06 | 2018-03-05 | Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908181XA true SG11201908181XA (en) | 2019-10-30 |
Family
ID=63448038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908181X SG11201908181XA (en) | 2017-03-06 | 2018-03-05 | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11091505B2 (fr) |
| EP (1) | EP3592362A4 (fr) |
| JP (2) | JP2020510661A (fr) |
| KR (1) | KR102603489B1 (fr) |
| CN (2) | CN117398398A (fr) |
| AU (1) | AU2018230991B2 (fr) |
| BR (1) | BR112019018447A2 (fr) |
| CA (1) | CA3055253A1 (fr) |
| IL (2) | IL301591A (fr) |
| MA (1) | MA47743A (fr) |
| MY (1) | MY196966A (fr) |
| PH (1) | PH12019502037A1 (fr) |
| SG (1) | SG11201908181XA (fr) |
| WO (1) | WO2018165048A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089365A1 (fr) | 2012-12-07 | 2014-06-12 | Venatorx Pharmaceuticals, Inc | Inhibiteurs de bêta-lactamase |
| WO2014110442A1 (fr) | 2013-01-10 | 2014-07-17 | VenatoRx Pharmaceuticals, Inc. | Inhibiteurs de bêta-lactamase |
| US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| ES2874579T3 (es) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| CN108472284A (zh) | 2015-09-11 | 2018-08-31 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| WO2017100537A1 (fr) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Inhibiteurs de bêta-lactamases |
| WO2018027062A1 (fr) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Composés contenant du bore |
| AU2018230991B2 (en) | 2017-03-06 | 2023-07-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| WO2018218154A1 (fr) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Inhibiteurs protéiques de liaison à la pénicilline |
| CN110959008A (zh) | 2017-05-26 | 2020-04-03 | 维纳拓尔斯制药公司 | 青霉素结合蛋白抑制剂 |
| CN113015532B (zh) | 2018-09-12 | 2024-03-15 | 维纳拓尔斯制药公司 | 包含β-内酰胺酶抑制剂的组合式组合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021454A (en) | 1911-01-23 | 1912-03-26 | Thomas Ernest Davis | Serving-table. |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| ES2457593T3 (es) | 2004-03-30 | 2014-04-28 | Millennium Pharmaceuticals, Inc. | Síntesis de bortezomib |
| CN1965838A (zh) | 2005-11-17 | 2007-05-23 | 李海超 | 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物 |
| CN101129382B (zh) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| AR069310A1 (es) | 2007-11-13 | 2010-01-13 | Protez Pharmaceuticals Inc | Inhibidores de beta- lactamasa |
| UA101966C2 (en) | 2008-01-18 | 2013-05-27 | Мерк Шарп Енд Доме Корп. | Beta-lactamase inhibitors |
| US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| ES2789177T3 (es) | 2010-08-10 | 2020-10-26 | Melinta Therapeutics Inc | Derivados de éster del ácido borónico cíclicos, procedimiento para la preparación y usos terapéuticos de los mismos |
| EP2768503A1 (fr) * | 2011-07-26 | 2014-08-27 | Wockhardt Limited | Compositions pharmaceutiques comprenant un antibiotique bêta-lactame, du sulbactam et un inhibiteur de bêta-lactamase |
| WO2013053372A1 (fr) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Inhibiteurs de type acide boronique de bêta-lactamases |
| KR101288157B1 (ko) | 2011-12-07 | 2013-07-19 | 백병하 | 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제 |
| JP5798495B2 (ja) | 2012-01-13 | 2015-10-21 | 住友理工株式会社 | 配線体接続構造体 |
| EP2814483A2 (fr) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Méthodes de traitement d'infections bactériennes |
| DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| WO2014089365A1 (fr) | 2012-12-07 | 2014-06-12 | Venatorx Pharmaceuticals, Inc | Inhibiteurs de bêta-lactamase |
| CA2894891A1 (fr) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Derives d'acide boronique et leurs utilisations therapeutiques |
| AU2014204046B2 (en) | 2013-01-04 | 2017-02-23 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2014110442A1 (fr) | 2013-01-10 | 2014-07-17 | VenatoRx Pharmaceuticals, Inc. | Inhibiteurs de bêta-lactamase |
| US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| WO2015157618A1 (fr) | 2014-04-11 | 2015-10-15 | The Texas A&M University System | Nouveaux inhibiteurs de la new delhi métallo-bêta-lactamase (ndm-1) |
| US20150361107A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
| ES2874579T3 (es) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| KR101935186B1 (ko) | 2014-09-04 | 2019-01-03 | 시오노기세야쿠 가부시키가이샤 | 카테콜기를 갖는 세팔로스포린류를 함유하는 제제 |
| ES2761778T3 (es) | 2014-12-19 | 2020-05-21 | Rempex Pharmaceuticals Inc | Aparato y proceso de flujo continuo para la producción de derivados de ácido borónico |
| CN108472284A (zh) | 2015-09-11 | 2018-08-31 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| CN105801610B (zh) | 2016-04-19 | 2018-05-18 | 武汉维舜医药科技有限公司 | 新型广谱β-内酰胺酶抑制剂 |
| ES2894251T3 (es) | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
| WO2018027062A1 (fr) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Composés contenant du bore |
| AU2018230991B2 (en) | 2017-03-06 | 2023-07-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| EP3802551A4 (fr) | 2018-05-25 | 2022-03-02 | Venatorx Pharmaceuticals, Inc. | Inhibiteurs de protéine de liaison à la pénicilline |
| CN113015532B (zh) | 2018-09-12 | 2024-03-15 | 维纳拓尔斯制药公司 | 包含β-内酰胺酶抑制剂的组合式组合物 |
| MA54319A (fr) | 2018-11-29 | 2021-10-06 | Venatorx Pharmaceuticals Inc | Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations |
-
2018
- 2018-03-05 AU AU2018230991A patent/AU2018230991B2/en active Active
- 2018-03-05 WO PCT/US2018/020968 patent/WO2018165048A1/fr unknown
- 2018-03-05 CN CN202311312855.3A patent/CN117398398A/zh active Pending
- 2018-03-05 KR KR1020197029086A patent/KR102603489B1/ko active IP Right Grant
- 2018-03-05 IL IL301591A patent/IL301591A/en unknown
- 2018-03-05 MY MYPI2019005139A patent/MY196966A/en unknown
- 2018-03-05 CN CN201880030083.5A patent/CN110678186A/zh active Pending
- 2018-03-05 JP JP2019547093A patent/JP2020510661A/ja active Pending
- 2018-03-05 IL IL268981A patent/IL268981B2/en unknown
- 2018-03-05 SG SG11201908181X patent/SG11201908181XA/en unknown
- 2018-03-05 MA MA047743A patent/MA47743A/fr unknown
- 2018-03-05 US US16/491,116 patent/US11091505B2/en active Active
- 2018-03-05 CA CA3055253A patent/CA3055253A1/fr active Pending
- 2018-03-05 BR BR112019018447A patent/BR112019018447A2/pt unknown
- 2018-03-05 EP EP18763383.9A patent/EP3592362A4/fr active Pending
-
2019
- 2019-09-06 PH PH12019502037A patent/PH12019502037A1/en unknown
-
2021
- 2021-06-21 US US17/353,377 patent/US11820784B2/en active Active
-
2023
- 2023-01-20 JP JP2023007546A patent/JP2023061946A/ja active Pending
- 2023-09-27 US US18/476,050 patent/US20240101580A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3592362A1 (fr) | 2020-01-15 |
| IL268981A (en) | 2019-10-31 |
| CN117398398A (zh) | 2024-01-16 |
| CA3055253A1 (fr) | 2018-09-13 |
| KR102603489B1 (ko) | 2023-11-16 |
| IL301591A (en) | 2023-05-01 |
| JP2023061946A (ja) | 2023-05-02 |
| EP3592362A4 (fr) | 2020-09-02 |
| WO2018165048A1 (fr) | 2018-09-13 |
| MY196966A (en) | 2023-05-15 |
| BR112019018447A2 (pt) | 2020-04-14 |
| US11091505B2 (en) | 2021-08-17 |
| AU2018230991A1 (en) | 2019-09-19 |
| CN110678186A (zh) | 2020-01-10 |
| PH12019502037A1 (en) | 2020-03-09 |
| IL268981B2 (en) | 2023-09-01 |
| US20200010485A1 (en) | 2020-01-09 |
| MA47743A (fr) | 2020-01-15 |
| IL268981B1 (en) | 2023-05-01 |
| JP2020510661A (ja) | 2020-04-09 |
| AU2018230991B2 (en) | 2023-07-13 |
| US11820784B2 (en) | 2023-11-21 |
| KR20190117790A (ko) | 2019-10-16 |
| US20240101580A1 (en) | 2024-03-28 |
| US20220002322A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908181XA (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
| SG11201807998WA (en) | Treatment Of Inflammatory Diseases With Inhibitors Of C5a Activity | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| SG11201811189RA (en) | Variant adeno-associated viruses and methods of using | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201805217XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11202000145XA (en) | Methods and systems for conditionally regulating gene expression | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201910198UA (en) | Multibiotic agents and methods of using the same | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201900464TA (en) | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201809751XA (en) | Egfr inhibitor compounds |